HK1244446A1 - Dna-肽組合疫苗 - Google Patents

Dna-肽組合疫苗

Info

Publication number
HK1244446A1
HK1244446A1 HK18104030.4A HK18104030A HK1244446A1 HK 1244446 A1 HK1244446 A1 HK 1244446A1 HK 18104030 A HK18104030 A HK 18104030A HK 1244446 A1 HK1244446 A1 HK 1244446A1
Authority
HK
Hong Kong
Prior art keywords
dna
combination vaccine
peptide combination
peptide
vaccine
Prior art date
Application number
HK18104030.4A
Other languages
English (en)
Inventor
Hironori Nakagami
Ryuichi Morishita
Hiroshi Koriyama
Hideki Tomioka
Kenji Naohara
Original Assignee
Anges Mg Inc
Univ Osaka
Ds Pharma Animal Health Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc, Univ Osaka, Ds Pharma Animal Health Co Ltd filed Critical Anges Mg Inc
Publication of HK1244446A1 publication Critical patent/HK1244446A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18104030.4A 2014-11-20 2018-03-23 Dna-肽組合疫苗 HK1244446A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014235736 2014-11-20
PCT/JP2015/082778 WO2016080540A1 (ja) 2014-11-20 2015-11-20 Ｄｎａ－ペプチド併用ワクチン

Publications (1)

Publication Number Publication Date
HK1244446A1 true HK1244446A1 (zh) 2018-08-10

Family

ID=56014070

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18104030.4A HK1244446A1 (zh) 2014-11-20 2018-03-23 Dna-肽組合疫苗
HK18108297.3A HK1248560A1 (zh) 2014-11-20 2018-06-28 Dna-肽組合疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18108297.3A HK1248560A1 (zh) 2014-11-20 2018-06-28 Dna-肽組合疫苗

Country Status (7)

Country Link
US (1) US10695420B2 (zh)
EP (1) EP3222289A4 (zh)
JP (1) JP6706821B2 (zh)
CN (1) CN107530408A (zh)
AU (2) AU2015350904A1 (zh)
HK (2) HK1244446A1 (zh)
WO (1) WO2016080540A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN109663124B (zh) * 2019-02-14 2022-05-13 武汉华纪元生物技术开发有限公司 针对人血管平滑肌细胞l型钙通道和血管紧张素1型受体的嵌合型二价降压疫苗及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
JP2004307477A (ja) 2003-03-24 2004-11-04 Kobe University 遺伝子導入型ワクチンの中和抗体誘導能を増強する方法、ワクチンの投与方法
EP2698164B1 (en) * 2011-04-15 2018-04-04 Osaka University Dna vaccine
JP6422022B2 (ja) 2012-08-31 2018-11-14 国立大学法人大阪大学 Ｖｅｇｆ及び／又はアンギオポエチン−２の特異的エピトープを含むｄｎａワクチン
JP6001974B2 (ja) 2012-09-21 2016-10-05 アンジェスＭｇ株式会社 アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン

Also Published As

Publication number Publication date
WO2016080540A1 (ja) 2016-05-26
EP3222289A4 (en) 2018-07-04
HK1248560A1 (zh) 2018-10-19
EP3222289A1 (en) 2017-09-27
AU2021218181A1 (en) 2021-09-09
JP6706821B2 (ja) 2020-06-10
CN107530408A (zh) 2018-01-02
US20170258895A1 (en) 2017-09-14
AU2015350904A1 (en) 2017-06-15
JPWO2016080540A1 (ja) 2017-08-31
US10695420B2 (en) 2020-06-30
AU2015350904A2 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
IL304663A (en) combination
IL286448A (en) auto-injector
GB201410971D0 (en) Vaccine
IL247073A0 (en) combination
GB201518684D0 (en) Vaccine
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
IL249823A0 (en) Meningococcus vaccines
IL248223B (en) Compositions of vaccine
IL247159B (en) Components of pcsk9
GB201522132D0 (en) Vaccine
GB201616904D0 (en) Vaccine
HK1248560A1 (zh) Dna-肽組合疫苗
GB201608821D0 (en) Vaccines
HUE053284T2 (hu) Vakcina
GB201402083D0 (en) Retaining means
HUE047467T2 (hu) Adjuvánsok
GB201417214D0 (en) Vaccine
GB201419061D0 (en) Conjugated Vaccine
GB201614387D0 (en) Improved vaccines
GB201603029D0 (en) Vaccine
GB201518917D0 (en) Vaccination
GB201406628D0 (en) Vaccine
GB201503266D0 (en) Vaccination
GB201416509D0 (en) Project P